NBIX:NGS-Neurocrine Biosciences Inc. (USD)

EQUITY | Drug Manufacturers - Specialty & Generic | Nasdaq Global Select

Last Closing

USD 140.55

Change

-1.10 (-0.78)%

Market Cap

USD 4.26B

Volume

0.54M

Analyst Target

USD 140.29
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Neurocrine Biosciences Inc discovers, develops and commercializes drugs for the treatment of neurological and endocrine-related diseases and disorders.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-05-21 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
VTRS Viatris Inc

-0.22 (-2.12%)

USD 12.47B
ITCI Intracellular Th

-0.64 (-0.94%)

USD 7.22B
LNTH Lantheus Holdings Inc

-0.82 (-1.02%)

USD 5.60B
ALKS Alkermes Plc

-0.31 (-1.25%)

USD 4.20B
ALVO Alvotech

-0.23 (-1.61%)

USD 3.99B
HCM HUTCHMED DRC

-0.52 (-2.79%)

USD 3.17B
INDV Indivior PLC Ordinary Shares

+0.24 (+1.47%)

USD 2.47B
DCPH Deciphera Pharmaceuticals LLC

N/A

USD 2.21B
AMPH Amphastar P

-0.14 (-0.34%)

USD 1.99B
EVO Evotec SE ADR

-0.01 (-0.22%)

USD 1.74B

ETFs Containing NBIX

IBRN iShares Trust - iShares N.. 4.74 % 0.00 %

-0.33 (-0.86%)

USD 3.84M
XY7D:XETRA Global X S&P 500® Covere.. 4.14 % 0.00 %

+0.05 (+-0.86%)

N/A
JSMD Janus Henderson Small/Mid.. 3.22 % 0.50 %

-0.91 (-0.86%)

USD 0.35B
HEAL:SW iShares Healthcare Innova.. 2.07 % 0.00 %

-0.06 (-0.86%)

N/A
2B78:F iShares Healthcare Innova.. 2.04 % 0.00 %

-0.07 (-0.86%)

N/A
AGED:SW iShares Ageing Population.. 0.68 % 0.00 %

-0.10 (-0.86%)

N/A
LABS 0.00 % 0.45 %

N/A

N/A
MDYG SPDR® S&P 400 Mid Cap Gr.. 0.00 % 0.15 %

-1.22 (-0.86%)

USD 2.45B
PBE Invesco Dynamic Biotechno.. 0.00 % 0.57 %

-0.54 (-0.86%)

USD 0.26B
AGES:LSE iShares IV Public Limited.. 0.00 % 0.00 %

+0.38 (+-0.86%)

USD 0.47B
DRDR:LSE iShares Healthcare Innova.. 0.00 % 0.00 %

-1.38 (-0.86%)

USD 1.06B
HEAL:LSE iShares Healthcare Innova.. 0.00 % 0.00 %

-0.07 (-0.86%)

USD 1.06B
2B78:XETRA iShares Healthcare Innova.. 0.00 % 0.00 %

-0.02 (-0.86%)

USD 1.14B

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 6.67% 64% D 67% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 6.67% 64% D 66% D+
Trailing 12 Months  
Capital Gain 50.10% 89% A- 88% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 50.10% 89% A- 88% B+
Trailing 5 Years  
Capital Gain 78.48% 86% B+ 79% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 78.48% 86% B+ 77% C+
Average Annual (5 Year Horizon)  
Capital Gain 6.87% 63% D 64% D
Dividend Return 6.87% 63% D 61% D-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 20.85% 92% A 75% C
Risk Adjusted Return 32.96% 86% B+ 67% D+
Market Capitalization 4.26B 100% F 94% A

Key Financial Ratios

  Ratio vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Ratio vs. Market (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 37.63 39% 26%
Price/Book Ratio 6.07 23% 18%
Price / Cash Flow Ratio 35.74 8% 8%
Price/Free Cash Flow Ratio 36.15 8% 6%
Management Effectiveness  
Return on Equity 18.16% 88% 88%
Return on Invested Capital 7.88% 81% 75%
Return on Assets 10.08% 92% 95%
Debt to Equity Ratio N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.